Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or quantitative data synthesis
PubMed 33071239 · doi:10.5009/gnl20032
What was done
Narrative review summarizing clinical and mechanistic concepts surrounding intestinal barrier dysfunction ("leaky gut"), dysbiosis, bacterial translocation, and altered bile acid metabolism in liver cirrhosis, as well as therapeutic approaches such as selective intestinal decontamination, disaccharides, and probiotics.
What was found
The abstract reports no quantitative metrics, sample sizes, or effect estimates. It qualitatively describes how delayed gut transit and dysbiosis lead to bacterial translocation and endotoxemia, which downregulate hepatic bile acid synthesis via CYP7A1 inhibition. Decreased abundance of 7alpha-dehydroxylating bacteria reduces secondary bile acid formation. Standard management of hepatic encephalopathy relies on nonabsorbable antibiotics and disaccharides, whereas Lactobacillus GG is noted to reduce endotoxemia and alter amino acid, vitamin, and secondary bile acid metabolism.
Why it matters
Synthesizes the pathophysiological crosstalk between intestinal barrier breakdown, bile acid dysregulation, and cirrhosis complications to frame the clinical rationale for microbiome-modulating therapies.
Limits
As a narrative review, it lacks a systematic literature search, formal quality appraisal, study inclusion counts, and quantitative meta-analysis. The abstract provides no specific patient numbers, effect sizes, or statistical confidence intervals.
Cited by
- supports Bile in the small intestine kills bacteria to prevent bacterial overgrowth.